Literature DB >> 2032864

Blood antibodies and uncrossmatched type O blood.

D Unkle1, R Smejkal, R Snyder, M Lessig, S E Ross.   

Abstract

The immediate transfusion of uncrossmatched type O blood in the initial resuscitation of the trauma victim remains controversial. To examine difficulties in crossmatching blood for later transfusions after use of uncrossmatched type O blood, we undertook a prospective 23-month study at a level I trauma center. One hundred thirty-five severely injured patients received uncrossmatched type O blood during the study period. Sixty-one patients (45%) died and 76 patients (56%) underwent emergent operation. There were no major transfusion reactions. Six patients had blood antigen-antibodies present on admission, and such antibodies developed in three patients during hospitalization. We conclude that uncrossmatched type O blood may be used safely in the exsanguinating patient, but blood antigen-antibodies, which may complicate later crossmatching, can develop after its use.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032864

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  3 in total

Review 1.  An approach to transfusion and hemorrhage in trauma: current perspectives on restrictive transfusion strategies.

Authors:  Homer Tien; Bartolomeu Nascimento; Jeannie Callum; Sandro Rizoli
Journal:  Can J Surg       Date:  2007-06       Impact factor: 2.089

Review 2.  Evolution of the role of army transfusion services in the management of trauma patients and battle casualties with massive hemorrhage.

Authors:  R S Sarkar; J Philip; S Kumar; Pramod Yadav
Journal:  Med J Armed Forces India       Date:  2012-08-21

3.  Safety of Uncrossmatched ABO-Compatible RBCs in Alloimmunized Patients with Bleeding: Data from Two Decades: Results of a Systematic Analysis in 6,109 Patients.

Authors:  Frauke Ringel; Helge Schoenfeld; Said El Bali; Jalid Sehouli; Claudia Spies; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2021-12-08       Impact factor: 4.040

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.